Skip to content

Carlos now

Leaping ahead of the news

  • Comic illustration of cheerful security analysts in a sunny office tracking a trail of glowing coins back towards a giant golden padlocked vault
    Gone in 20 Minutes: How Hackers Drained $6.3 Billion From Binance in the Biggest Crypto Heist Ever Finance & Real Estate
  • Comic illustration: What Would You Do If a Bear Joined Your Forest Photo Shoot
    What Would You Do If a Bear Joined Your Forest Photo Shoot? Entertainment & Social Media View
  • Comic illustration: Can Shiny Pants and Three Colours Turn a Dance Into Pop Art
    Can Shiny Pants and Three Colours Turn a Dance Into Pop Art? Entertainment & Social Media View
  • Comic illustration: Is Digging for Pirate Gold Really the Best Beach Workout
    Is Digging for Pirate Gold Really the Best Beach Workout? Entertainment & Social Media View
  • Bright comic of friendly cartoon scientists with a thermometer on a sunny glacier, a smiling penguin and polar bear beside melting ice
    Earth’s Ice Has a Long Memory: UN Reports Warn That Overshooting 1.5°C Brings Irreversible Losses Culture & Knowledge
  • Bright comic illustration of a smiling cartoon scientist in a sunny lab holding a glowing DNA helix next to a friendly cartoon liver character, both facing the viewer
    First Prime Editing Inside the Human Body: A One-Time Fix for Wilson Disease Enters the Clinic Health & Sports
  • Bright comic of two smiling cartoon politicians in suits with clear faces facing the viewer handing over a rolled document with a red ribbon in a sunlit stone hall, with cheerful colleagues seated at a table behind them
    Herzog Taps Gadi Eisenkot to Form Israel’s Next Government as He Calls for a ‘National Emergency Government’ Politics
  • Comic illustration: Can You Fix a Car With Magic Words and High Heels
    Can You Fix a Car With Magic Words and High Heels? Entertainment & Social Media View
Comic illustration of a smiling eye doctor showing an eye model to a patient holding an injection pen in a bright clinic

FDA Orders Blindness Warning on Ozempic, Wegovy and Other GLP-1 Drugs Over Rare Eye Condition NAION

Posted on November 11, 2026 By Carlos now - SI ideas & work

Millions of people around the world now take a weekly injection to lose weight or control their blood sugar. This week, the US Food and Drug Administration (FDA) told the makers of the best-known GLP-1 drugs that their labels must carry a new warning: a rare eye condition that can lead to sudden, permanent loss of vision in one eye.

The order covers Ozempic, Wegovy, Mounjaro and Zepbound, the medicines that have turned GLP-1 treatments into one of the biggest stories in modern pharmaceuticals. The condition in question has a long name, nonarteritic anterior ischemic optic neuropathy, usually shortened to NAION. It is not a new disease, but the regulator now says the evidence is strong enough that patients and doctors should be told about it in black and white.

NAION happens when the small blood vessels that supply the optic nerve become blocked. Deprived of oxygen, the nerve that carries images from the eye to the brain is damaged. According to the FDA, the result is typically a painless decrease in vision in one eye, and that loss can be permanent. There is no known treatment that reverses vision loss caused by NAION. The American Academy of Ophthalmology describes it as the most common cause of acute optic nerve injury in people over 50.

The FDA said it based its decision on a detailed review of NAION reports among GLP-1 users, together with other published studies. Its conclusion is carefully worded: there is an “increased risk of rare NAION events” in people taking these drugs. What the regulator does not yet know is why. It also acknowledged a major complication in the research: many people who take GLP-1 medicines for obesity or type 2 diabetes already carry risk factors for NAION, such as problems with blood vessels and circulation, regardless of the drug.

That nuance is why the reaction from doctors has been measured rather than alarmed. In a statement, the American Academy of Ophthalmology said that “any added risk appears small, and it has not been established that these medications cause NAION.” The academy stressed that GLP-1 medicines offer important benefits for people with diabetes, obesity and heart disease, and gave patients a simple two-part message: do not stop your medication without talking to your doctor, and if you notice sudden, painless vision loss in one eye, see an ophthalmologist promptly.

Novo Nordisk, which makes Ozempic and Wegovy, also pushed back on the idea of a proven link. The company said it believes the data “do not establish a cause-and-effect relationship”, while adding that NAION “can have a profound impact on patients and their families” and that patient safety remains a top priority. Novo said it would continue to monitor the safety of its medicines.

What the research says so far

The question of GLP-1 drugs and eye health has been building for several years. Two years ago, US researchers published a study analysing around 17,000 patients and found that those taking semaglutide, the active ingredient in Ozempic and Wegovy, were four times more likely to be diagnosed with NAION than people who were not on the drug. The figure made headlines, but one of the study’s authors, Harvard Medical School ophthalmology professor Dr Joseph Rizzo, described the findings as “significant but tentative”. He called for more research, especially in a more diverse group of patients, before firm conclusions are drawn.

European regulators have also looked at the issue. Last year, a safety committee of the European Medicines Agency said that NAION may affect up to 1 in 10,000 people taking semaglutide. That places it firmly in the category of very rare side effects, but with GLP-1 prescriptions running into the millions, even a very rare event can affect a meaningful number of people in absolute terms.

The new US warning therefore does two things at once. It does not say the drugs are unsafe, and it does not tell anyone to stop treatment. But it formally recognises that the signal seen in studies and case reports is real enough to belong on the label, which is where doctors and patients look when they weigh benefits against risks.

The GLP-1 labels already list several other possible problems. They carry warnings about pancreatitis and gallbladder disease, and the most common side effects of semaglutide are well known to anyone who has taken it: nausea, vomiting and stomach pain. NAION now joins that list as a rare but potentially serious item.

For patients, the practical advice is straightforward. Vision changes that come on suddenly, especially in one eye and without pain, should never be brushed aside as tiredness or screen strain. Because NAION is painless, people sometimes notice it only when they wake up and find part of their field of vision dim or blurred. Prompt examination by an eye specialist matters, both to confirm the diagnosis and to rule out other causes that can be treated.

Doctors, meanwhile, are likely to pay closer attention to patients who already have several risk factors for optic nerve problems. That could include a closer look at eye health before treatment begins, and a clear conversation about what symptoms to watch for. For many patients with severe obesity, diabetes or heart disease, the benefits of GLP-1 therapy are substantial, from better blood sugar control to weight loss and lower cardiovascular risk. The new label is meant to make that trade-off more transparent, not to tip it automatically one way or the other.

The decision also reflects how quickly these medicines have moved from niche diabetes drugs to mass-market treatments. As more people take them for longer periods, regulators gain far more data than was available in the original clinical trials, and rare side effects that were invisible in a few thousand trial participants can become measurable in millions of real-world users. Label updates such as this one are a normal part of that process.

What remains open is the biological question at the heart of the warning. Researchers still need to explain whether GLP-1 drugs themselves affect blood flow to the optic nerve, whether rapid changes in blood sugar or weight play a role, or whether the link mostly reflects the underlying health of the people who take them. Until those answers arrive, the message from regulators and eye doctors is the same: the risk is small, but it is real enough to know about, and sudden vision loss in one eye is always a reason to see a specialist without delay.

Carlos now related posts:

  • Bright comic illustration of a smiling cartoon scientist in a sunny lab holding a glowing DNA helix next to a friendly cartoon liver character, both facing the viewer
    First Prime Editing Inside the Human Body: A…
  • Comic illustration of a shop manager and a technician with a laptop in front of overheated supermarket freezers
    France Blames Iran’s Revolutionary Guards for Cyber…
  • Comic illustration of three concerned travelers with luggage and a sleeping child waiting in a sunny airport terminal with parked airplanes outside
    Longest US Flight Shutdown Since 9/11: How…
  • Comic illustration of a smiling pharmacist and business analyst in a sunny pharmacy beside a rising green arrow made of medicine boxes and injector pens
    Weight-Loss Boom Pushes Eli Lilly's 2026 Revenue…
  • Bright comic illustration of a cheerful young woman on a sunny park bench flipping a big toggle switch beside her phone, turning a swirl of video cards into a calm stream of friend bubbles
    Australia Wants an Off Switch for Social Media…
  • Comic illustration of serious executives in a sunlit boardroom gathered around a glowing green computer chip next to an empty leather chair
    Jensen Huang Resigns as Nvidia CEO: Colette Kress…
Health & Sports Tags:Eye Health, FDA, GLP-1, Ozempic, Weight Loss

Post navigation

Previous Post: ‘Cruise for Life’ Ship Villa Vie Odyssey Seized in Singapore After Running Out of Money
Next Post: Does a Compliment From a Stranger Count When the Dog Agrees?

Related Posts

  • Bright comic illustration of a smiling cartoon scientist in a sunny lab holding a glowing DNA helix next to a friendly cartoon liver character, both facing the viewer
    First Prime Editing Inside the Human Body: A One-Time Fix for Wilson Disease Enters the Clinic Health & Sports
  • Bright comic illustration of a friendly eye with a tiny glowing microchip next to camera glasses under a sunny pastel sky
    A Chip in the Eye Lets a Stargardt Patient Read a Word Again Health & Sports
  • Bright comic illustration of three smiling health workers with a clipboard and a cooler box standing in front of a small green-roofed village clinic on a sunny day
    Ebola Reaches an Eighth Congolese Province as Cases Pass 9,400, Even as New Infections Slow Health & Sports
  • Bright comic illustration of a smiling doctor handing a bottle of water to a cheerful grandmother under a shady tree in a sunny European town square
    Europe’s Hottest Summer Killed More Than 50,000 People in Its Cities, Study Finds Health & Sports

Archives

  • November 2026
  • October 2026

Categories

  • Automotive & Technology
  • Business & Economy
  • Computers & Digital
  • Culture & Knowledge
  • Entertainment – Oriental Erotica
  • Entertainment & Social Media View
  • Entertainment nsfw (password protected: 1111)
  • Finance & Real Estate
  • Food & Drink
  • Health & Sports
  • Politics
  • Tourism Travel & Leisure

Recent Posts

  • AI-Assisted Proof of the Riemann Hypothesis Passes Independent Checks: Why Mathematicians Are Stunned
  • Wall Street Enters Correction: S&P 500 Suffers Worst Week in 18 Months as AI Stocks Tumble
  • Is Trying On Everything in the Store a Sport Yet?
  • Google Picks Blue Origin’s New Glenn to Launch Project Suncatcher AI Satellites in 2029
  • BepiColombo Arrives at Mercury: Europe and Japan’s Probe Enters Orbit After an Eight-Year Journey

Carlos now – high to the air cloud with tags:

AI Video Anthropic Artificial Intelligence Behind the Scenes carlosnow China Climate Change Coalition Cybersecurity Dance Dogs Donald Trump El Niño ESA European Union Fashion France Friends Funny Glamour Google High Heels Hilltop Inflation Interest Rates IPO Japan JAXA Mars Mathematics Middle East Music Video Nasdaq NSFW Nvidia Ocean Science Photo Shoot Russia Semiconductors Shopping Space Exploration Stock Market TikTok Travel Ukraine

Pages at Carlos now

  • About
  • Bright comic of two smiling cartoon calligraphy students with clear faces facing the viewer in a sunny Japanese classroom with brush, inkstone and blank paper
    UNESCO Body Recommends Japanese Calligraphy Shodo for World Intangible Heritage List Culture & Knowledge
  • Comic illustration: Can You Fall Asleep in a Hallway and Wake Up in a Fairy Tree
    Can You Fall Asleep in a Hallway and Wake Up in a Fairy Tree? Entertainment & Social Media View
  • Bright comic of a smiling Japanese grandmother with a flashlight, a teenage boy, a young girl and a rescue worker with clear faces facing the viewer on a sunny street with fallen roof tiles and a broken flower pot after an earthquake
    Magnitude 5.7 Earthquake Jolts Central Japan Overnight, Injuring More Than 20 in Aichi and Shizuoka Culture & Knowledge
  • Comic illustration: Who Knew a Gas Station Could Be a Paparazzi Hotspot
    Who Knew a Gas Station Could Be a Paparazzi Hotspot? Entertainment & Social Media View
  • Bright comic illustration of two hands shaking above a glowing light bulb over a sunny city with a power plant and white doves
    Trump Declares an Energy Ceasefire in Ukraine, Then Russian Drones Hit Power Plants in Kyiv and Kharkiv Politics
  • Comic illustration of a smiling flight attendant in a navy uniform strolling through a sunny city plaza with her suitcase
    What Does a Flight Attendant Really Do on a Layover? Entertainment & Social Media View
  • Comic illustration of two smiling scientists in a sunny mission control room watching a small spacecraft arrive at the planet Mercury near the bright Sun
    BepiColombo Arrives at Mercury: Europe and Japan’s Probe Enters Orbit After an Eight-Year Journey Culture & Knowledge
  • Bright comic illustration of friendly cartoon graphs, golden coins and an academic cap under a soft pastel daylight sky
    Nobel Prize in Economics Goes to Robert Hall and Michael Woodford for Rebuilding the Science of Steering Economies Business & Economy

© MMXXVI carlosnow.com by Telemedia Asia Friends

Powered by PressBook News WordPress theme